COVID-19 and chronic rhinosinusitis: management and comorbidity - what have we learned?
Expert review of clinical immunology(2023)
摘要
Intranasal corticosteroids remain the standard treatment for CRS in patients with SARS-CoV-2 infection. Indications for surgical treatment of CRS should be critically evaluated and reserved for patients with complications and those with no other treatment options. For this purpose, COVID-19 status should be known if possible and, in case of unclear status (emergency), using appropriate personal protective equipment. Systemic corticosteroids should be avoided were possible. Biological treatment should be continued under careful monitoring in uninfected patients and should be temporarily interrupted during COVID-19 infection.
更多查看译文
关键词
chronic rhinosinusitis, COVID-19, SARS-CoV-2, nasal polyps, CRSwNP, biologics, intranasal corticosteroids, ACE2 receptor expression, >
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要